University of British Columbia

Amorfix Life Sciences Limited

Promis Neurosciences Inc.

University of Saskatchewan

Other

University Health Network

Helix Biopharma Corporation

Neil R Cashman

Steven S Plotkin

Avijit Chakrabartty

Rishi Rakhit

Andrew A Potter

Johanne Kaplan

Scott Napper

Joachim Bernhard Ostermann

Lorne A Babiuk

Marni Diane Uger

Philip Griebel

Peter Hedlin

Veronica Ciolfi

Xubiao Peng

Ebrima Gibbs

Judith Maxwell Silverman

Wah Yau Wong

Horacio Uri Saragovi

Baomin Tian

Viengthong Chai

William C Guest

Heman Lap-Man Chao

Véronique Guillemard

Kristen Marciniuk

Sanjay Kalra

Ryan Taschuk

Douglas L Arnold

Marty Lehto

Marty Letho

The disclosure pertains to conformational epitopes in alpha-synuclein, antibodies thereto and methods of making and using immunogens and antibodies specific thereto. In particular antibodies raised to cyclic compounds comprising at least 3 amino acids of EKTKEQ (SEQ ID NO: 1) selectively recognize misfolded oligomeric alpha-synuclein and are able to inhibit alpha-synuclein propagation and toxicity.

Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof

The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies. Also provided are chimeric or humanized antibodies, including antibodies having CDRs in Table 2 and/or having a sequence as set forth in Table 4B or a sequence with at least 50% sequence identity thereto optionally wherein the CDR amino acid sequences are as set for forth in SEQ ID Nos: 74-79. Also provided are methods and uses thereof as well as kits comprising said antibodies.

Humanized antibodies binding to amyloid-beta (A-beta)

The disclosure pertains to N-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto

The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies.

Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers

The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide

The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide

The disclosure pertains to methods of treating or preventing a disease or condition associated with and/or induced by soluble A-beta oligomer such as Alzheimer's disease by administering to a subject in need thereof conformation specific and/or selective antibodies or binding fragments thereof and related products.

Compositions comprising cyclic peptides derived from an A-beta peptide

The disclosure pertains to conformational epitopes in TDP-43, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto

Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide

A method and system to identify an epitope unique to a misfolded form of a protein is provided. Sets of one or more amino acid residues are selected from a model representing the structure of the protein; the free energy of unfolding of each set is determined; and the epitope is identified from the sets having a total probability of unfolding above a minimum probability or a free energy of unfolding below a minimum energy. In other aspects, the invention provides for the use of epitopes identified by the epitope prediction methods, and related antibodies, to diagnose and treat disease and to screen samples for the presence of such epitopes.

Methods and systems for predicting misfolded protein epitopes

Provided herein are an exogenous antibody that binds selectively to a misfolded form of human FasR, and methods and uses for said antibody. Specifically disclosed is the antibody designated AMF 3a-118 which selectively binds the peptide represented by LHHDGQFCH (SEQ ID NO:2) and the antibody designated AMF 3d-19 which selectively binds the peptide represented by NSTVCEH (SEQ ID NO:5).

FasR antibodies and methods of use

A novel constrained peptide epitope derived from A&#x3b2;, related antibody compositions and methods of use. An isolated antibody that specifically binds to a cyclic peptide comprising the conformational epitope corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric A&#x3b2; is described. An antigenic peptide comprising an epitope having a constrained cyclic configuration, corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric A&#x3b2; is also described. Methods of treating, preventing, and diagnosing Alzheimer's disease are also described.

Oligomer-specific amyloid beta epitope and antibodies

Growing community of inventors

Vancouver, Canada

Neil R Cashman